Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
Top Page
Wockhardt Limited
(WOCKPHARMA)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹1,253.00
▼(-10.85% Downside)
Action:ReiteratedDate:12/02/25
Wockhardt Limited's overall stock score reflects significant financial challenges, with persistent net losses and negative cash flows being the most impactful factors. Technical analysis shows mixed signals, with short-term strength but potential long-term weakness. The negative P/E ratio and lack of dividend yield further weigh down the score.
Positive Factors
Improving Gross Margin & Revenue Growth
Sustained revenue growth with a materially higher gross margin suggests improving product mix, pricing power or manufacturing efficiency. These drivers support longer‑term margin sustainability and provide a foundation to fund operational improvements and rebuild profitability over months.
Negative Factors
Negative Operating and Free Cash Flow
Negative operating and free cash flow constrains the company’s ability to self‑fund R&D, capacity upkeep and regulatory compliance. Reliance on external funding increases financial risk and can limit strategic choices, impeding durable recovery and investment for the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Gross Margin & Revenue Growth
Sustained revenue growth with a materially higher gross margin suggests improving product mix, pricing power or manufacturing efficiency. These drivers support longer‑term margin sustainability and provide a foundation to fund operational improvements and rebuild profitability over months.
Read all positive factors
Wockhardt Limited (WOCKPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹206.70B
Dividend YieldN/A
Average Volume (3M)24.00K
Price to Earnings (P/E)100.2
Beta (1Y)1.52
Revenue Growth1.19%
EPS Growth93.08%
CountryIN
Employees2,386
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)3.63
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio5.29
Price to Book (P/B)5.18
Price to Sales (P/S)7.42
P/FCF Ratio-85.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wockhardt Limited Business Overview & Revenue Model
Company Description
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and inter...
How the Company Makes Money
Wockhardt primarily makes money by selling pharmaceutical products and related supplies across domestic and export markets. Its key revenue streams generally include: (1) Finished dosage formulations: revenue from manufacturing and selling branded...
Wockhardt Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
58
Neutral
Cash Flow
42
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.07B | 30.35B | 28.30B | 26.57B | 32.30B | 27.08B |
| Gross Profit | 16.72B | 18.26B | 15.98B | 14.85B | 18.81B | 14.98B |
| EBITDA | 4.53B | 3.60B | 1.38B | 420.00M | 2.26B | -1.43B |
| Net Income | -230.00M | -470.00M | -4.63B | -5.59B | -2.44B | 6.86B |
Balance Sheet | ||||||
| Total Assets | 85.33B | 81.35B | 76.49B | 76.83B | 82.43B | 77.73B |
| Cash, Cash Equivalents and Short-Term Investments | 9.30B | 6.13B | 5.23B | 1.50B | 3.79B | 2.38B |
| Total Debt | 24.56B | 20.21B | 23.56B | 21.84B | 21.98B | 26.73B |
| Total Liabilities | 36.57B | 34.78B | 39.87B | 40.21B | 40.41B | 40.12B |
| Stockholders Equity | 45.67B | 43.53B | 33.59B | 33.54B | 38.49B | 33.77B |
Cash Flow | ||||||
| Free Cash Flow | 1.19B | -2.64B | 30.00M | -560.00M | 2.01B | -4.53B |
| Operating Cash Flow | 1.89B | -220.00M | 2.19B | 1.53B | 4.13B | -2.87B |
| Investing Cash Flow | -4.17B | -7.83B | -1.37B | -1.25B | -2.01B | 14.70B |
| Financing Cash Flow | 2.97B | 4.09B | 3.34B | -3.15B | -710.00M | -11.71B |
Wockhardt Limited Technical Analysis
Neutral
1405.55
Price Trends
1319.29
Negative
1347.37
Negative
1447.99
Negative
Market Momentum
-33.56
Negative
52.13
Neutral
81.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WOCKPHARMA, the sentiment is Neutral. The current price of 1405.55 is above the 20-day moving average (MA) of 1231.60, above the 50-day MA of 1319.29, and below the 200-day MA of 1447.99, indicating a neutral trend. The MACD of -33.56 indicates Negative momentum. The RSI at 52.13 is Neutral, neither overbought nor oversold. The STOCH value of 81.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:WOCKPHARMA.
Wockhardt Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹775.92B | 18.87 | ― | 0.33% | 7.33% | -3.79% | |
73 Outperform | ₹376.92B | 27.58 | ― | 0.28% | 9.66% | 25.79% | |
72 Outperform | ₹628.57B | 25.97 | ― | 0.80% | 9.32% | 11.25% | |
70 Outperform | ₹1.02T | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
53 Neutral | ₹591.01B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹206.70B | 100.15 | ― | ― | 1.19% | 93.08% |
* Healthcare Sector Average
IN:WOCKPHARMA
Wockhardt Limited
1,272.10
59.30
4.89%
IN:ALKEM
Alkem Laboratories Ltd.
5,257.10
602.35
12.94%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,335.95
244.95
22.45%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,217.60
135.81
12.55%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,094.30
656.58
45.67%
IN:IPCALAB
IPCA Laboratories Limited
1,485.95
186.85
14.38%
Wockhardt Limited Corporate Events
Wockhardt Opens SEBI-Mandated Window for Transfer of Physical Shares
Feb 20, 2026
Wockhardt Limited has informed stock exchanges that it has published a newspaper advertisement announcing a special window for re-lodgement of transfer requests for physical shares. The initiative follows a recent SEBI circular aimed at easing inv...
Wockhardt earns independent ‘Aspiring’ ESG rating for 2025
Feb 19, 2026
Wockhardt Limited has been assigned an overall ESG score of 65, rated as “Aspiring,” for 2025 by NSE Sustainability Ratings and Analytics, a SEBI-registered ESG rating provider. The assessment, based solely on public disclosures and in...
Wockhardt’s Foviscu Matches Meropenem in Phase 3, Bolstering Antibiotic Pipeline
Jan 27, 2026
Wockhardt has reported that its novel intravenous antibiotic Foviscu (WCK 4282) met the primary endpoint in a pivotal Phase 3 trial for complicated urinary tract infections and acute pyelonephritis caused by Gram-negative bacteria, including ESBL-...
Wockhardt Receives Independently Assigned ESG Rating of 70 for 2025
Jan 16, 2026
Wockhardt Limited has disclosed that CFC Finlease Private Limited, a SEBI-licensed ESG rating provider, has independently assigned the company an ESG rating of 70 for the year 2025, based solely on Wockhardt’s public disclosures and other pu...
Wockhardt Seeks Pan-European Approval for Novel Antibiotic WCK 5222
Jan 7, 2026
Wockhardt has filed a Marketing Authorisation Application with the European Medicines Agency for its novel antibiotic WCK 5222, branded as Zaynich, a fixed-dose combination of Zidebactam and Cefepime designed to treat resistant Gram-negative infec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.